Amy Apostoleris

Strategic Development Leader collaborating with organizations to develop and drive innovative solutions and business strategies within Healthcare and Pharma

[Damon Imani @damonimani]

My response to The View hosts on Charlie Kirk’s assassination

[Elon Musk @elonmusk]

Wow, this is crazy!

[Amy Apostoleris @AmyApostoleris]

@trumprealparody A

[Sarepta Therapeutics @Sarepta]

Congratulations to the recipients of the 2023 Route 79 Scholarships! Now in its 6th year, the program provides academic scholarships to those living with #Duchenne and siblings in Duchenne families to support post-secondary educational goals. Read more: https://t.co/tbSMRU31jx

[Medocity, Inc. @MedocityInc]

@MedocityInc’s proprietary REACH™️ solution recruits and qualifies patients for LSO PSPs, including those of specified race, culture, demographics and SDOH to help remove barriers to participation. To learn more, contact @Loreenmmarshall.
#patientsfirst #techquity #REACHplatform

[Medocity, Inc. @MedocityInc]

Nonadherence, per the @NIH, is often due to #forgetfulness, #illiteracy & #lackoftrust.

To learn how @Medocity’s digital patient support solutions provide a #personalized, interactive experience throughout the #carejourney while improving #outcomes, contact @Loreenmmarshall.

[Medocity, Inc. @MedocityInc]

@MedocityInc is solving key challenges for gene therapy clinical trials. Our innovative digital solutions improve the quality of patient candidates, decrease screening fail rates, reduce study timelines, and enhance site relationships. Contact @AmyApostoleris to schedule a demo.

[Medocity, Inc. @MedocityInc]

Today's successful PSP are tailored, dynamic, streamlined, interoperable & holistic.

@MedocityInc's digital solutions meet these criteria with personalized, evolving, seamless care journeys that connect, support & engage patients in real-time. DM @loreenmmarshall to learn more.

[Medocity, Inc. @MedocityInc]

In a rare disease clinical program, @MedocityInc’s REACH™ Platform increased patient identification & decreased enrollment timelines across all trials.

Learn more about REACH & this case study at https://t.co/LVn18jk4UV or by contacting @AmyApostoleris.

#REACHPlatform #DCT

[Medocity, Inc. @MedocityInc]

We're looking forward to the Decentralized Clinical Trials Conference next week!

Visit our booth to learn more about our REACH™️ technology, participate in a demo, & get a Starbucks gift card on us!

Use the BOOK NOW button to schedule your demo time now.

See you in Boston!

[Medocity, Inc. @MedocityInc]

💡Check out our latest blog about the need for LSOs to continuously adapt & evolve with changes in regulations, technology, & patient needs, while staying focused on nurturing authentic care & building strategic teams: https://t.co/kjGZYriSvf
#patientsfirst #digitalpatientsupport

[Medocity, Inc. @MedocityInc]

Last month, @MedocityInc’s @loreenmmarshall presented “Cell & Gene Therapies: Creating A Digital Ecosystem Strategy to Ensure a Smooth Patient Journey"

https://t.co/MKNgWA6fZn

Listen in to learn how to create patient-centric, digital butterflies for cell & gene therapies. 📱🦋

[Medocity, Inc. @MedocityInc]

Understanding trust is key to clinical trial recruitment & enrollment success, @MedocityInc developed REACH™️, a patient recruitment, eligibility, & enrollment solution that accelerates timelines, reduces dropouts, & improves retention.

Contact @AmyApostoleris to learn more.

[Medocity, Inc. @MedocityInc]

🌴😎📱 @MedocityInc is excited to be attending #OCTWestCoast this year!

Stop by Booth #34 today to meet @karenkeeley14 & learn more about #Medocity’s REACH™️ Platform, which improves #recruitment & #enrollment in rare disease studies.

#patientsfirst #REACHPlatform

[Medocity, Inc. @MedocityInc]

Are you having challenges with your #recruitment and #enrollment efforts for #raredisease studies?

Connect with @KarenKeeley14 next week at the #OCTWestCoast conference to discuss how our REACH™️ solution can help you meet or exceed your enrollment goals.

#patientsfirst

[Medocity, Inc. @MedocityInc]

@MedocityInc's #REACHplatform ingests #RWD data from 50B claim transactions, 350M lives & 2.3M HCPs to provide a heterogeneous view of patients, providers & outcomes to increase recruitment & accelerate timelines.

To learn more, contact @AmyApostoleris.

[Medocity, Inc. @MedocityInc]

🤔🔦💡ICYMII....

@Fishawack's C&GT report stressed pharma should increase focus on areas such as #healthequity, #patientfocused #drugdevelopment, & #clinicaltrialdiversity.

For more on @MedocityInc’s digital C&GT solutions, contact @loreenmmarshall.

https://t.co/lwVjvmK3RB

[Amy Apostoleris @AmyApostoleris]

https://t.co/AoPt6CCmbn

[Amy Apostoleris @AmyApostoleris]

https://t.co/8nGImhyWJn

[Medocity, Inc. @MedocityInc]

November is #LungCancerAwarenessMonth.

Join @MedocityInc working to increase awareness about preventative screenings and the symptoms of this deadly disease. Your life or the life of someone you love may depend upon it.

#lungcancerawareness #preventativescreening #digitalcare